NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on
the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and
gene therapies for rare diseases, today announced the appointment of Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer
(“CMO”). Dr. Sersch will oversee the clinical development of Mustang’s pipeline in CAR T technology and gene therapies.
Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “We are delighted to welcome
Martina to the Mustang leadership team. Her extensive global immuno-oncology drug development expertise and vast array of
experience in bringing innovative oncology products to market will help guide Mustang’s clinical development efforts and regulatory
strategies in an exciting time of growth for the company.”
Dr. Sersch is an experienced drug developer and physician with specialty training in oncology, infectious and
tropical diseases. She has more than 17 years of experience in early- and late-stage clinical development in academia and industry.
Prior to joining Mustang, Dr. Sersch served as executive director at Amgen, where she successfully led supplemental Biologics
License Application filings in the area of hematology, as well as indication strategies for early- and late-stage compounds in
hematology. Prior to Amgen, Dr. Sersch held positions of increasing responsibility on regional and global levels in oncology drug
development, including novel immuno-oncology drugs at IRAD Oncology, Genentech, Roche and Pfizer. At Roche, Dr. Sersch was
instrumental in the biologics strategy, where she led initiatives globally and regionally with a specific focus in Asia Pacific and
China, including supporting the development of regional guidelines for drug development. Dr. Sersch obtained her medical and
graduate degrees from Heidelberg University in Germany and subsequently trained in England, South Africa and the United States.
Dr. Sersch said, “I am thrilled to join Mustang to help advance the development of its CAR T and
CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as its lentiviral gene therapy for XSCID. I look forward to
working with the Mustang team as we strive to deliver promising new treatment options for patients and their families in areas of
unmet medical need.”
About Mustang Bio
Mustang Bio, Inc. (“Mustang”), is a clinical?stage biopharmaceutical company focused on the development and
commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene
therapies in areas of unmet need. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an
ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered
with top medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers,
as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and
files periodic reports with the U.S. Securities and Exchange Commission. For more information, visit www.mustangbio.com.
Forward?Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any
statements relating to our growth strategy and product development programs and any other statements that are not historical facts.
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to
differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform
under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development
activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and
clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early
stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual
property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required
by law.
Company Contact:
Jaclyn Jaffe
Mustang Bio, Inc.
(781) 652-4500
ir@mustangbio.com
Investor Relations Contact:
Jeremy Feffer
Managing Director, LifeSci Advisors, LLC
(212) 915-2568
jeremy@lifesciadvisors.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 940-0135
tplohoros@6degreespr.com
![MustangBioLogo.jpg](https://resource.globenewswire.com/media/75bd19b8-c298-4600-953e-f9b6215c043c/small/mustangbiologo-jpg.jpg)
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2MzkjNzQwMjE3NA==)